Development of pathogenesis and therapeutics in myeloproliferative neoplasms
10.3760/cma.j.issn.1009-9921.2015.07.005
- VernacularTitle:骨髓增殖性肿瘤分子发病机制及治疗研究进展
- Author:
Quan QIU
;
Mangju WANG
;
Ping ZHU
- Publication Type:Journal Article
- Keywords:
Myeloproliferative neoplasms;
Molecular mechanism;
Therapy
- From:
Journal of Leukemia & Lymphoma
2015;24(7):400-404
- CountryChina
- Language:Chinese
-
Abstract:
This article introduces the genes related to pathogenesis and prognosis of myeloproliferative neoplasms (MPN) and the current situation of MPN domestic and overseas,which have been reported in the 56th ASH annual meeting.It is emphasized on essential evaluation of the risk score using IPSET in ET,Tefferi in PV and DIPSS-plus in PMF separately.It has assessed advancements in allogeneic hematopoietic stem cell transplantation,phlebotomy,cytoreductive therapy and drug therapy.The article pays more attention to aspirin,anagrelide,JAK2 targeted agent ruxolitinib and thalidomide which is domestically used in the treatment of PMF.
